Oculis Holding AG (OCS) Receivables - Other (2021 - 2025)
Oculis Holding AG (OCS) posted quarterly Receivables - Other of $13.3 million for Q4 2025, up 305.86% year-over-year from $3.3 million in Q4 2024, and up 305.86% quarter-over-quarter from $3.3 million in Q4 2024.
Oculis Holding AG (OCS) Receivables - Other (2021 - 2025) Analysis & Trends
Oculis Holding AG's Receivables - Other history runs 5 years deep, the most recent figure standing at $13.3 million for Q4 2025.
- In Q4 2025, Receivables - Other rose 305.86% year-over-year to $13.3 million; the TTM figure through Dec 2025 stood at $13.3 million (up 305.86% YoY), while the FY2025 annual figure was $12.9 million, up 292.91% from the prior year.
- Receivables - Other for Q4 2025 stood at $13.3 million, up from $3.3 million in the prior quarter.
- The five-year high for Receivables - Other was $13.3 million in Q4 2025, with the low at $1038.0 in Q4 2022.
- The 5-year median for Receivables - Other is $2.4 million (2023), against an average of $3.8 million.
- The sharpest annual moves came in 2022 and 2023: Receivables - Other plunged 96.7% in 2022, then surged 232859.95% in 2023.
- Oculis Holding AG's Receivables - Other stood at $31450.6 in 2021, then slumped by 96.7% to $1038.0 in 2022, then soared by 232859.95% to $2.4 million in 2023, then jumped by 35.86% to $3.3 million in 2024, then jumped by 305.86% to $13.3 million in 2025.
- Business Quant data shows OCS's Receivables - Other at $13.3 million in Q4 2025, $3.3 million in Q4 2024, and $2.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.33 Mn |
| Dec 31, 2025 | 13.33 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 2.42 Mn |
| Dec 31, 2023 | 2.42 Mn |
| Dec 31, 2022 | 1,038.02 |
| Dec 31, 2022 | 1,038.02 |
| Dec 31, 2021 | 31,450.56 |
| Dec 31, 2021 | 31,450.56 |